Jul 13, 2023
|
Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China
|
Jun 29, 2023
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
Jun 5, 2023
|
Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase
|
May 31, 2023
|
Ardelyx to Present at the Jefferies 2023 Healthcare Conference
|
May 23, 2023
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
May 17, 2023
|
Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)
|
May 15, 2023
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
May 9, 2023
|
Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
|
May 3, 2023
|
Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
|
May 1, 2023
|
Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
|